The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

By J. Schrader, S. Lüders, A. Kulschewski, J. Berger, W. Zidek, J. Treib, K. Einhäupl, H. Diener, P. Dominiak. Stroke, 2003

658 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, result): “The same was the case for the Acute Candesartan Cilexetil Therapy in Stroke Survival (ACCESS) study [543], which suggested benefits of candesartan given for 7 days after acute stroke.”
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, result): “The same was the case for the Acute Candesartan Cilexetil Therapy in Stroke Survival (ACCESS) study [543], which suggested benefits of candesartan given for 7 days after acute stroke.”
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, background): “The ACCESS [846], SCAST [847], PRoFESS sub-”
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (2013, background): “A few preliminary randomized trials of blood pressure lowering in acute ischemic stroke have been published.(411,413,431) A placebo-controlled randomized trial tested oral nimodipine starting within 48 hours after ischemic stroke onset in 350 patients.”